Beam Therapeutics posts wider-than-expected Q3 net loss as revenue drops
BEAM•Beam Therapeutics reported a Q3 net loss of $134.41 million, wider than the $116.21 million consensus estimate, while license and collaboration revenue fell to $307,000. It ended the quarter with $1.0 billion in cash and expects its runway to extend into mid-2029.
1. Quarterly results
Beam Therapeutics reported a Q3 operating loss of $141.32 million, compared with the $122.72 million consensus estimate. Operating expenses were $141.63 million, including marginally higher research and development expenses and increased general and administrative costs. License and collaboration revenue declined sharply year over year to $307,000.
2. Cash and program outlook
The company ended Q3 with $1.0 billion in cash and expects its runway to extend into mid-2029. Beam expects to complete dosing in the BEAM-302 pivotal cohort in the first half of 2027, submit a U.S. biologics license application for risto-cel in sickle cell disease as early as year-end 2026, and begin dosing in the BEAM-304 Phase 1/2 trial in PKU in early 2027.
